139524-57-5

Basic information

• Product Name: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER
• Synonyms: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER;1,4-Dioxa-7-azaspiro[4.4]nonane-7-carboxylic acid, phenylMethyl ester;Benzyl 1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxylate
• CAS NO: 139524-57-5
• Molecular Formula: C₁₄H₁₇NO₄
• Molecular Weight: 263.28908
• Mol File: 139524-57-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER(139524-57-5)
• EPA Substance Registry System: 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER(139524-57-5)

Safety Data

• Hazardous Substances Data: 139524-57-5(Hazardous Substances Data)

Usage

General Description

1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER is a chemical compound with a complex and specific molecular structure. It is classified as a carboxylic acid benzyl ester, and contains a spiro ring and a dioxane ring. 1,4-DIOXA-7-AZA-SPIRO[4.4]NONANE-7-CARBOXYLIC ACID BENZYL ESTER has potential industrial and pharmaceutical applications due to its unique structure and properties. However, its exact uses and potential hazards are not specified and should be further investigated and understood before handling or using this compound.

Upstream product

• 620-73-5 phenyl chloroacetate 
• 95656-88-5 benzyl 3-hydroxypyrrolidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 107-21-1 ethylene glycol 
• 130312-02-6 benzyl 3-oxopyrrolidine-1-carboxylate 
• 107-15-3 ethylenediamine 

Downstream Products

• 959689-68-0 diethyl 2-(1-(benzyloxycarbonyl)-3-(2-hydroxyethoxy)pyrrolidine-3-carboximidamidooxy)but-2-enedioate 
• 139524-61-1 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-7-aza-spiro[4.4]non-7-yl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 139524-59-7 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-7-aza-spiro[4.4]non-7-yl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 176-33-0 1,4-dioxa-6-azaspiro[4.4]nonane 

Relevant articles and documents

HETEROCYCLIC COMPOUND

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation

A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological properties, for studies in two canine atrial fibrillation (AF) models. The three compounds converted AF in both models, but only compound 26 was shown to be orally bioavailable. Resolution of the racemate 26 into its corresponding enantiomers 40 and 41 and subsequent biological testing of these enantiomers led to the selection of (1S,2S)-1-(1-naphthalenethoxy)-2-(3- ketopyrrolidinyl)cyclohexane monohydrochloride (41) as a potential atrial selective antiarrhythmic candidate for further development.

Preparation and in Vitro and in Vivo Evaluation of Quinolones with Selective Activity against Gram-Positive Organisms

A series of quinolones were prepared which contained oximes or substituted oximes as replacements for the amine substituents normally found on the pyrrolidine or piperidine fragments of quinolone antibacterial agents.These substituents led to compounds that had selective activity against Gram-positive organisms.These compounds showed in vivo activity Staphylococcus aureus.Only compound 29 had in vivo activity against Streptococcus pneumoniae.